NewsBenzinga阿斯利康针对Sone-Ve的BLA已被美国受理并获优先审评,用于CLDN18.2阳性晚期胃癌/胃食管结合部癌患者的二线及后线治疗;PDUFA目标日期预计为2027年第二季度 阿斯利康针对Sone-Ve的BLA已被美国受理并获优先审评,用于CLDN18.2阳性晚期胃癌/胃食管结合部癌患者的二线及后线治疗;PDUFA目标日期预计为2027年第二季度 Benzinga 2026.11.19 12:16 (GMT+0) Open on Benzinga Other news Biohaven's Phase 1 Data Presented In Oral Plenary Session At ENA 2026 Shows Deep, Durable Responses In Patients With FGFR3-Altered Urothelial Cancer And Head And Neck Squamous Cell Carcinoma Clearmind Medicine Publishes Hong Kong Patent Application Covering Innovative Psychedelic Compounds Targeting Treatment Of PTSD And Other Mental Health Disorders Warner Music Gr Q4 Adj. EPS $0.55 Beats $0.36 Estimate, Sales $2.001B Beat $1.906B Estimate Biohaven Presents Clinical Data From Ongoing Phase 1 Study Of BHV-1530, Potential FGFR3-Directed ADC With Topoisomerase I Payload, At ENA 2026 Bernstein Maintains Outperform on Agilon Health, Raises Price Target to $138 Palo Alto Networks Stock Soars: Investors Cheer Strong Outlook, Applied Compute Acquisition
Biohaven's Phase 1 Data Presented In Oral Plenary Session At ENA 2026 Shows Deep, Durable Responses In Patients With FGFR3-Altered Urothelial Cancer And Head And Neck Squamous Cell Carcinoma
Clearmind Medicine Publishes Hong Kong Patent Application Covering Innovative Psychedelic Compounds Targeting Treatment Of PTSD And Other Mental Health Disorders
Biohaven Presents Clinical Data From Ongoing Phase 1 Study Of BHV-1530, Potential FGFR3-Directed ADC With Topoisomerase I Payload, At ENA 2026